172 related articles for article (PubMed ID: 36077198)
1. Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum.
Skrzypski M; Kołodziejski PA; Pruszyńska-Oszmałek E; Wojciechowicz T; Janicka P; Krążek M; Małek E; Strowski MZ; Nowak KW
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077198
[TBL] [Abstract][Full Text] [Related]
2. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity.
Gao S; Ghoshal S; Zhang L; Stevens JR; McCommis KS; Finck BN; Lopaschuk GD; Butler AA
J Biol Chem; 2019 Sep; 294(36):13366-13377. PubMed ID: 31324719
[TBL] [Abstract][Full Text] [Related]
3. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production.
Thapa D; Xie B; Manning JR; Zhang M; Stoner MW; Huckestein BR; Edmunds LR; Zhang X; Dedousis NL; O'Doherty RM; Jurczak MJ; Scott I
Physiol Rep; 2019 Apr; 7(8):e14043. PubMed ID: 31004398
[TBL] [Abstract][Full Text] [Related]
4. Expression of Circulating MicroRNAs and Myokines and Interactions with Serum Osteopontin in Type 2 Diabetic Patients with Moderate and Poor Glycemic Control: A Biochemical and Molecular Study.
Al-Rawaf HA; Alghadir AH; Gabr SA
Biomed Res Int; 2021; 2021():7453000. PubMed ID: 34917685
[TBL] [Abstract][Full Text] [Related]
5. Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function.
Kołodziejski PA; Pruszyńska-Oszmałek E; Strowski MZ; Nowak KW
Endocrine; 2017 Jun; 56(3):538-550. PubMed ID: 28477305
[TBL] [Abstract][Full Text] [Related]
6. Adropin inhibited tilapia hepatic glucose output and triglyceride accumulation via AMPK activation.
Zhang C; Zhang Q; Huang Z; Jiang Q
J Endocrinol; 2020 Aug; 246(2):109-122. PubMed ID: 32485680
[TBL] [Abstract][Full Text] [Related]
7. Adropin regulates hepatic glucose production via PP2A/AMPK pathway in insulin-resistant hepatocytes.
Chen X; Chen S; Shen T; Yang W; Chen Q; Zhang P; You Y; Sun X; Xu H; Tang Y; Mi J; Yang Y; Ling W
FASEB J; 2020 Aug; 34(8):10056-10072. PubMed ID: 32579277
[TBL] [Abstract][Full Text] [Related]
8. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
9. Adropin deficiency is associated with increased adiposity and insulin resistance.
Ganesh Kumar K; Zhang J; Gao S; Rossi J; McGuinness OP; Halem HH; Culler MD; Mynatt RL; Butler AA
Obesity (Silver Spring); 2012 Jul; 20(7):1394-402. PubMed ID: 22318315
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction.
Banerjee S; Ghoshal S; Stevens JR; McCommis KS; Gao S; Castro-Sepulveda M; Mizgier ML; Girardet C; Kumar KG; Galgani JE; Niehoff ML; Farr SA; Zhang J; Butler AA
J Biol Chem; 2020 Oct; 295(40):13753-13768. PubMed ID: 32727846
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats.
Akcilar R; Kocak FE; Simsek H; Akcilar A; Bayat Z; Ece E; Kokdasgil H
Bratisl Lek Listy; 2016; 117(2):100-5. PubMed ID: 26830041
[TBL] [Abstract][Full Text] [Related]
12. Adropin's Role in Energy Homeostasis and Metabolic Disorders.
Ali II; D'Souza C; Singh J; Adeghate E
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955453
[TBL] [Abstract][Full Text] [Related]
13. Hepatic adropin is regulated by estrogen and contributes to adverse metabolic phenotypes in ovariectomized mice.
Stokar J; Gurt I; Cohen-Kfir E; Yakubovsky O; Hallak N; Benyamini H; Lishinsky N; Offir N; Tam J; Dresner-Pollak R
Mol Metab; 2022 Jun; 60():101482. PubMed ID: 35364299
[TBL] [Abstract][Full Text] [Related]
14. Supplementation of persimmon leaf ameliorates hyperglycemia, dyslipidemia and hepatic fat accumulation in type 2 diabetic mice.
Jung UJ; Park YB; Kim SR; Choi MS
PLoS One; 2012; 7(11):e49030. PubMed ID: 23145054
[TBL] [Abstract][Full Text] [Related]
15. Role of adropin in arterial stiffening associated with obesity and type 2 diabetes.
Jurrissen TJ; Ramirez-Perez FI; Cabral-Amador FJ; Soares RN; Pettit-Mee RJ; Betancourt-Cortes EE; McMillan NJ; Sharma N; Rocha HNM; Fujie S; Morales-Quinones M; Lazo-Fernandez Y; Butler AA; Banerjee S; Sacks HS; Ibdah JA; Parks EJ; Rector RS; Manrique-Acevedo C; Martinez-Lemus LA; Padilla J
Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H879-H891. PubMed ID: 36083795
[TBL] [Abstract][Full Text] [Related]
16. The effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia.
Akcılar R; Emel Koçak F; Şimşek H; Akcılar A; Bayat Z; Ece E; Kökdaşgil H
Iran J Basic Med Sci; 2016 Mar; 19(3):245-51. PubMed ID: 27114793
[TBL] [Abstract][Full Text] [Related]
17. Bile acid binding resin improves hepatic insulin sensitivity by reducing cholesterol but not triglyceride levels in the liver.
Tagawa H; Irie J; Itoh A; Kusumoto Y; Kato M; Kobayashi N; Tanaka K; Morinaga R; Fujita M; Nakajima Y; Morimoto K; Sugizaki T; Kawano Y; Yamada S; Kawai T; Watanabe M; Itoh H
Diabetes Res Clin Pract; 2015 Jul; 109(1):85-94. PubMed ID: 25981325
[TBL] [Abstract][Full Text] [Related]
18. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C
Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844
[TBL] [Abstract][Full Text] [Related]
19. A STUDY OF THE ASSESSMENT OF SERUM ADROPIN LEVEL AS A RISK FACTOR OF ISCHAEMIC HEART DISEASE IN TYPE 2 DIABETES MELLITUS CASES.
Mansour HK; Makboul K; Elhalawany SH; Ibrahim BE; Marawan DA
Georgian Med News; 2022; (328-329):115-117. PubMed ID: 36318853
[TBL] [Abstract][Full Text] [Related]
20. Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes.
Flynn CR; Albaugh VL; Tamboli RA; Gregory JM; Bosompem A; Sidani RM; Winnick JJ
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G370-G374. PubMed ID: 31709832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
